Abstract
Approved for the treatment of epilepsy and migraine prophylaxis, topiramate also acts as a carbonic anhydrase inhibitor implying a potential role in the treatment of pseudotumor cerebri (PTC). Topiramate has a propensity to cause anorexia with consequent weight loss, which alone may be curative in PTC. Prescribers must be aware of several reported cases of acute secondary angle-closure glaucoma reported in patients treated with topiramate.
Original language | English (US) |
---|---|
Pages (from-to) | 15-17 |
Number of pages | 3 |
Journal | Seminars in Ophthalmology |
Volume | 21 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2006 |
Keywords
- Glaucoma
- Pseudotumor cerebri
- Topiramate
- Weight loss
ASJC Scopus subject areas
- Ophthalmology